薛园：创新药领域科学家和创业者背后的“铸剑人”

Core Insights - The Chinese biopharmaceutical industry is undergoing a transformation, moving from imitation to original innovation, with companies like BeiGene and Innovent Biologics leading the way [2][3] Group 1: Industry Development Stages - The Chinese biopharmaceutical industry can be divided into three stages: copying innovation (before 2015), follow-on innovation (2015-2025), and original innovation (post-2025) [2] - The original innovation stage is characterized by companies achieving groundbreaking innovations in new targets, compounds, and mechanisms, positioning them as leaders in the global market [2] Group 2: Market Potential and Growth - By 2035, the Chinese innovative drug market is projected to reach 3.5 trillion yuan, accounting for 15% of the global market [3] - China ranks second globally in pharmaceutical industry scale, with approximately 30% of the world's innovative drugs currently under research [3] Group 3: Investment and Ecosystem - The Beijing Life Science Park Venture Capital Fund focuses on transforming scientific achievements from research institutions and universities into viable businesses, particularly in biopharmaceuticals and high-growth sectors [4] - The fund benefits from a robust ecosystem in the Zhongguancun Life Science Park, which fosters collaboration among biopharmaceutical professionals and provides a complete industry chain [4][5] Group 4: Support for Entrepreneurs - The fund aims to be a "warm partner" for scientists and entrepreneurs, providing comprehensive support from project transformation to resource linking and financing [6][7] - The investment philosophy emphasizes long-term commitment to solving real medical needs and ensuring clinical benefits for patients [7]